Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Nathan H. Fowler, MD, Judith Trotman, MBChB, FRACP, FRCPA, Rebecca Auer, MRCP, FRPath, PhD, Christopher R. Flowers, MD MS, William F. Reed, MD, Elena Ivanova, PhD, Jane Huang, MD, Pier Luigi Zinzani, MD PhD

Blood (2019) 134 (Supplement_1): 5252.

https://doi.org/10.1182/blood-2019-122628

Published: 2019

Journal Articles

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, William Reed, MD, Chris Tankersley, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 5256.

https://doi.org/10.1182/blood-2019-122629

Published: 2019

Journal Articles

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Naveen Pemmaraju, MD, Krishna Gundabolu, MBBS, Kristen Pettit, MD, Moshe Talpaz, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Peter Eisenberg, MD, Hagop Youssoufian, MD, Susan Duggan, RN, MBA, Barbara Wallner, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 4178.

https://doi.org/10.1182/blood-2019-130310

Published: 2019

Journal Articles

Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Adekemi Taylor, PhD, Martine Allard, PhD, Cecile Kresja, PhD, Dana Lee, PharmD, Greg Slatter, PhD

Blood (2019) 134 (Supplement_1): 5768.

https://doi.org/10.1182/blood-2019-131481

Published: 2019

Journal Articles

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Blood (2018) 132 (Supplement 1): 2674.

https://doi.org/10.1182/blood-2018-99-111727

Published: 2018

Journal Articles

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Manuel Ayala, MD, Jacqueline Domínguez, NL, Iván Bonilla, MD

Blood (2016) 128 (22): 5430.

https://doi.org/10.1182/blood.V128.22.5430.5430

Published: 2016

Journal Articles

Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Lotte E. van der Wagen, MD, Liane te Boome, MD, Inger Nijhof, MD, Marieke Schoordijk, Ellen Meijer, MD PhD, Jurgen Kuball, MD PhD

Blood (2016) 128 (22): 4565.

https://doi.org/10.1182/blood.V128.22.4565.4565

Published: 2016

Journal Articles

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

Tara L. Lin, MD, Laura F. Newell, MD, Robert K. Stuart, MD, Laura C. Michaelis, MD, Stephen E. Rubenstein, MD, Helen S. Pentikis, PhD, Timothy Callahan, PhD, Donna Alvarez, Lawrence D. Mayer, PhD, Arthur C. Louie, MD

Blood (2015) 126 (23): 2510.

https://doi.org/10.1182/blood.V126.23.2510.2510

Published: 2015

Journal Articles

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

Antonio M Risitano, MD PhD, Michael Storek, Leonardo Sahelijo, MD, Mittie Doyle, Yang Dai, Ilene Ceil Weitz, MD, Judith C.W. Marsh, MD, Modupe Elebute, MBChB, MD, Casey L O'Connell, MD, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Giridharan Ramsingh, MD, Serena Marotta, MD, Andrzej Hellmann, Ante S. Lundberg, MD

Blood (2015) 126 (23): 2137.

https://doi.org/10.1182/blood.V126.23.2137.2137

Published: 2015

Journal Articles

A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study

Robert B Kleiman, Rajesh Chopra, de Haan Hans, Kristen Hege, Angela J James, Xiaomin Wang, Xiaoling Wu, Edward O'Mara

Blood (2015) 126 (23): 5555.

https://doi.org/10.1182/blood.V126.23.5555.5555

Published: 2015

Journal Articles

The Effect of IV Iron Therapy on HIF Pathway and HIF Regulated Genes in Elderly Patients with Unexplained Anemia

Levon Katsakhyan, BS, Sabina Swierczek, PhD, Andrew Artz, MD MS, Elizabeth A Price, MD MPH, Stanley L. Schrier, MD, Harvey Jay Cohen, MD, Josef T. Prchal, MD, Victor R. Gordeuk, MD

Blood (2015) 126 (23): 4533.

https://doi.org/10.1182/blood.V126.23.4533.4533

Published: 2015

Journal Articles

Reactivation of the X-Chromosome Genes within PV Clone

Soo Jin Kim, MS, Jaroslav Jelinek, MD PhD, Jean-Pierre J Issa, MD, Josef T. Prchal, MD, Sabina Swierczek, PhD

Blood (2015) 126 (23): 4086.

https://doi.org/10.1182/blood.V126.23.4086.4086

Published: 2015

Journal Articles

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Hongming Zhu, Jiong Hu, Li Chen, Wei Zhou, Xiaoyang Li, Wang Lining, Xia Zhao, Yunxiang Zhang, Huijin Zhao, Yu Chen, Huiping Sun, Qiusheng Chen, Yu Chen, Weili Zhao, Jianqing Mi, Zhixiang Shen, Saijuan Chen, Zhenyi Wang, Junmin Li, MD PhD

Blood (2014) 124 (21): 282.

https://doi.org/10.1182/blood.V124.21.282.282

Published: 2014

Journal Articles

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

Raoul Herbrecht, MD, Mario Ojeda-Uribe, MD, Daniel Kientz, MD, Alain Bohbot, MD, Olivier Hinschberger, MD, Cecile Fohrer, MD, Kun-Lun Liu, MD, Emilie Remy, Christine Ernst, MD, Laurence Corash, MD, Jean-Pierre Cazenave, MD, PhD

Blood (2013) 122 (21): 4820.

https://doi.org/10.1182/blood.V122.21.4820.4820

Published: 2013

Journal Articles

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Sheeba K. Thomas, MD, Alexander Suvorov, MD, Lucien Noens, MD, PhD, Oleg Rukavitsin, MD, Joseph Fay, MD, Ka Lung Wu, MD, PhD, Todd M Zimmerman, MD, Helgi van de Velde, MD, PhD, Rajesh Bandekar, PhD, Thomas A Puchalski, PharmD, Ming Qi, MD, PhD, Clarissa Uhlar, PhD, Olga S Samoilova, MD

Blood (2012) 120 (21): 2972.

https://doi.org/10.1182/blood.V120.21.2972.2972

Published: 2012

Journal Articles

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Jorge E. Cortes, MD, Alexander E Perl, MD, Hervé Dombret, MD, Sabine Kayser, Björn Steffen, MD, Philippe Rousselot, MD, PhD, Giovanni Martinelli, MD, PhD, Elihu H. Estey, MD, Alan K Burnett, MD, Guy Gammon, MD, Denise Trone, Eugen Leo, MD, PhD, MBA, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 48.

https://doi.org/10.1182/blood.V120.21.48.48

Published: 2012

Journal Articles

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Marika Masselli, Serena Pillozzi, Massimo D'Amico, Luca Gasparoli, Olivia Crociani, Matteo Stefanini, Kennet Mugridge, Wolfang Tiedke, Andrea Becchetti, Annarosa Arcangeli, MD, PhD

Blood (2012) 120 (21): 1506.

https://doi.org/10.1182/blood.V120.21.1506.1506

Published: 2012

Journal Articles

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, James M. Foran, MD, FRCPC, Darejan Ghirdaladze, Mamia Zodelava, Gautam Borthakur, M.D., Guy Gammon, MD, Denise Trone, Robert C Armstrong, Ph.D., Joyce James, Mark J. Levis, MD, PhD

Blood (2012) 120 (21): 1507.

https://doi.org/10.1182/blood.V120.21.1507.1507

Published: 2012

Journal Articles

“Boldness be my friend” (Shakespeare; Cymbeline )

Jessica K. Altman, Martin S. Tallman

Blood (2011) 118 (25): 6477–6478.

https://doi.org/10.1182/blood-2011-11-386557

Published: 2011

NARROW

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Randomized Phase 2 Zanubrutinib (BGB-3111) + Obinutuzumab Vs Obinutuzumab Monotherapy in Patients with Relapsed/Refractory Follicular Lymphoma (R/R FL)

Phase 2 Study of Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis

Concentration-QTc (C-QTc) Analysis of the MDM2 Inhibitor KRT-232 (formerly AMG 232) in Subjects with Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Cardiotoxicity Secondary to Tyrosine Kinase Inhibitors 2nd Generation in Mexican Patients with Chronic Myeloid Leukemia

Effective Treatment of Severe Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients

A Novel Approach to QTc Studies: Assessing Cardiac Safety of the mTOR Kinase Inhibitor CC-223 within the Dose-Escalation/Expansion Study

The Effect of IV Iron Therapy on HIF Pathway and HIF Regulated Genes in Elderly Patients with Unexplained Anemia

Reactivation of the X-Chromosome Genes within PV Clone

Long-Term Follow-up of Survival, Complications, Arsenic Retention and Quality of Life in Patients with Newly Diagnosed Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid/Arsenic Trioxide Combination Therapy

Comparative Effectiveness and Safety Of Pathogen Inactivated (Amotosalen-UVA) and Conventional Plasma For Treatment Of Auto-Immmune Thrombotic Thrombocytopenic Purpura (TTP): A 15-Year Retrospective Review

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients ≥ 60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia

Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias

Final Results of A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Quizartinib (AC220) Administered Daily to Patients with Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FLT3-ITD Status

“Boldness be my friend” (Shakespeare; Cymbeline )

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only